UK markets close in 7 hours 22 minutes

Spexis AG (PPHOF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.50000.0000 (0.00%)
At close: 01:21PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.5000
Open2.5000
BidN/A x N/A
AskN/A x N/A
Day's range2.5000 - 2.5000
52-week range2.5000 - 2.5000
Volume1,000
Avg. volume0
Market cap28.891M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-3.9800
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Spexis provides business update

    Ad hoc announcement pursuant to Art. 53 LRCash position to finance operations extended into January 2023Resources focused on advancing lead program, Phase 3 ColiFin®Assessment of balixafortide development options continues; balixafortide PK/safety clinical trial in renally impaired subjects completed; results expected to be reported this fallProgress in earlier-stage pipeline derived from macrocycle platformVariety of partnering and funding options being vigorously exploredCompany renews equity-

  • EQS Group

    Spexis announces business update call to be held on July 28th

    Spexis AG / Key word(s): ConferenceSpexis announces business update call to be held on July 28th 25.07.2022 / 19:25 Allschwil, Switzerland, July 20, 2022Spexis announces business update call to be held on July 28th Conference call scheduled for Thursday, July 28, 2022, at 8 AM EDT / 2 PM CETSpexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a business update call on Thursday, July 28, 2022, at 8 AM ED

  • EQS Group

    Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model

    Spexis AG / Key word(s): Research UpdateSpexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model 07.07.2022 / 07:30 Allschwil, Switzerland, July 7, 2022Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical modelSPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhi